About CHA Biotech
CHA Biotech is a publicly listed company based in Seongnam-si (South Korea) founded in 2000. Stem cell therapeutics are developed for degenerative and ischemic conditions. The company has 334 employees. CHA Biotech has completed 1 acquisition, including Kakao Healthcare. Its chief executive, as recorded, is Sang Hoon Oh. Its website chabio.com draws about 32 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Developer of stem cell therapeutics. The companys pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The companys adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetalNPC (Nerve Progenitor Cell) for Parkinsons disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
- Headquarters Seongnam-si, South Korea
- Employees 334
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website chabio.com
- Legal Name Cha Biotech Co., Ltd.
- Annual Revenue$879.38 M (USD)21.36as on Dec 31, 2025
- Net Profit-$76.08 M (USD)-2206.57as on Dec 31, 2025
- EBITDA-$591.13 K (USD)94.3as on Dec 31, 2025
- Latest Funding Round$67.82M (USD), Post-IPO
Jan 2026
- InvestorsHanwha Life
& 1 more
- Employee Count334
- Investments & Acquisitions
Funding Insights of CHA Biotech
- Total Rounds 1
- Last Round Post-IPO — $67.82M
- First Round $67.82M
(Jan 2026)
- Investors Count 2
All 1 funding rounds of CHA Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $67.82M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in CHA Biotech
CHA Biotech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Hanwha Life and Hanwha General Insurance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| hanwhalife.com | ||||
| hwgeneralins.com |
Investor details for CHA Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CHA Biotech
1 people are tracked at CHA Biotech (1 in leadership); the tracked headcount is 334.
| Name | Role | Group |
|---|---|---|
Sang Hoon Oh | CEO | Leadership |
Complete people profiles for CHA Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CHA Biotech
CHA Biotech is a publicly listed company on the KRX with ticker symbol 085660 in South Korea, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Dec 2005
- Listed onKRX: 085660
- Listed entityCHA Biotech Co., Ltd.
- Exchange sectorElectronic technology
- ISINKR7085660009
- Share price7,710.00 KRW (+0.13% on the day) · 2026-10-14
- Market capitalisation715,890,921,783.00 KRW
- EPS (diluted, trailing year)-135.73 KRW
- Volume (last session)203,810
Financials of CHA Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,270.00B KRW | -109.88B KRW | -853.7M KRW |
| 2024 | 1,050.00B KRW | -4.76B KRW | -14.97B KRW |
| 2023 | 953.95B KRW | -8.43B KRW | 28.45B KRW |
| 2022 | 844.58B KRW | -47.54B KRW | -20.89B KRW |
| 2021 | 727.48B KRW | -13.97B KRW | 33.86B KRW |
Detailed financial statements for CHA Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CHA Biotech
CHA Biotech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kakao Healthcare.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Offers comprehensive healthcare data analytics services. | kakaohealthcare.com | Seongnam-si, South Korea | 2022 | Nov 2025 | $54.5M |
Complete acquisition details for CHA Biotech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CHA Biotech
4 dated milestones of CHA Biotech across 26 years, from founding to its latest funding, stage changes and deals.
- Founded CHA Biotech is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Kakao Healthcare.
- Funding First funding round of $67.8M.
Web traffic of CHA Biotech
The website of CHA Biotech (chabio.com) receives about 31.6K visits a month and ranks #767,207 among all websites worldwide, #901 in Biotechnology and Pharmaceuticals.
- Monthly visits31.6K
▲ 14.8% vs previous month
- Unique visitors9.4K
per month
- Global rank#767,207
among all websites
- Category rank#901
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit5.0
- Average visit1 min 09 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with CHA Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| daewonpharm.com | 100% | 95.4K | View details | ||
| ildong.com | 89% | 79.3K | #344,860 | View details | |
| yuhan.co.kr | 89% | #155,074 | View details | ||
icord.com | icord.com | 80% | #1,662,861 | – | |
| medicopharma.co.kr | 76% | #596,014 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for CHA Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cha Biotech
Complete news archive for CHA Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CHA Biotech
CHA Biotech was founded in 2000 and raised its 1st funding round 26 years after it was founded.
CHA Biotech is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Sang Hoon Oh is the CEO of CHA Biotech, as recorded in our data.
CHA Biotech has 334 employees.
Annual revenue of CHA Biotech is $879.38M as on Dec 31, 2025.
Developer of stem cell therapeutics. The companys pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The companys adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetalNPC (Nerve Progenitor Cell) for Parkinsons disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
Yes, CHA Biotech is publicly traded on KRX under the ticker symbol 085660.
CHA Biotech has made 1 acquisition, including Kakao Healthcare.
CHA Biotech has 2 investors. Key investors include Hanwha Life, and Hanwha General Insurance.